An interventional study of Yishen Qutong Granules and Yishen Qutong Simulant Granules in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 5 open to participants now, 9 under way, none of them phase 3. Esophageal Squamous Cell Carcinoma · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is one of 3 that started in 2024, is one of 2 with no phase, and was the 5th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →5 of the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–85
By country, each count listing its studies:
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4
First in 2018; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 536 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 121 across the 6 interventional studies, 550 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
3 of the studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06342167Cancer Institute and Hospital, Chinese Academy of Medical SciencesEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | 2026-12-01 |
| NCT07147361Cancer Institute and Hospital, Chinese Academy of Medical SciencesPredictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma | 2026-12-31 |
| NCT05951127Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdditional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Esophageal cancer is a high - incidence cancer type in China, characterized by high incidence, high mortality, and low survival rates. Over 90% of esophageal cancer cases in China are squamous cell carcinoma, while in Western countries, approximately 80% are adenocarcinomas. Current international guidelines, including those of the NCCN and CSCO, are not entirely suitable for the diagnosis and treatment of esophageal cancer in the Chinese context. In recent years, although the 5 - year survival rate for esophageal cancer has improved, significant challenges remain, such as severe side effects during chemoradiotherapy and targeted - immunotherapy, decreased patient tolerance and quality of life, and even interruption of treatment.
To leverage the synergistic role of traditional Chinese medicine (TCM) in the treatment of major diseases, this study, which builds on previous research, is founded on the theory of "reinforcing healthy qi to strengthen the body, removing toxins, and resolving stasis." It aims to conduct a multicenter, randomized, controlled clinical trial of the TCM formula Yishen Qutong Granules, designed to reinforce healthy qi to strengthen the body and remove toxins, in combination with neoadjuvant concurrent therapy for locally advanced esophageal squamous cell carcinoma. The study will enroll 268 patients (1:1 ratio) with locally advanced esophageal squamous cell carcinoma (cTNM stage III - IVa) who are expected to undergo neoadjuvant concurrent therapy and are potentially resectable. On the basis of conventional Western medical treatment, the treatment group will be administered the patented TCM formula Yishen Qutong Granules orally, while the control group will receive a Yishen Qutong Simulated Granules orally.
The primary outcome measure will be the clinical benefit rate (CBR, CBR = CR + PR + SD), with secondary outcomes including pathological response rate (mPR), R0 resection rate, and TCM syndrome symptom score. The study aims to establish an objective evaluation system for the efficacy and safety of combined treatment based on the integration of disease and syndrome differentiation. It will also elucidate the mechanisms underlying the therapeutic effects of Yishen Qutong Granules.
This study is a randomized, double-blind, placebo-controlled clinical trial. The objective is to verify the efficacy and safety of Yishen Qutong Granules, a traditional Chinese medicine (TCM) for reinforcing healthy qi to strengthen the body and remove toxins, in combination with neoadjuvant concurrent chemoradiotherapy or neoadjuvant concurrent chemoimmunotherapy for locally advanced esophageal cancer that is expected to be resectable.
Patients will be recruited from the Cancer Hospital of the Chinese Academy of Medical Sciences and other collaborating clinical units involved in this project. The study will include two cohorts:
Yishen Qutong Granules have been approved as an in-house preparation by the Beijing Municipal Drug Administration (Beijing Drug Preparation No. Z20200072000). The formula consists of the following ingredients: Rehmannia glutinosa (20 g), Drynaria fortunei (10 g), Oldenlandia diffusa (10 g), Scutellaria barbata (10 g), Pheretima aspergillum (10 g), Dioscorea opposita (15 g), Cornus officinalis (15 g), Moutan cortex (10 g), Alisma plantago-aquatica (10 g), and Poria cocos (10 g). In this formula, Rehmannia glutinosa serves as the principal herb, nourishing yin and kidney essence, and enriching marrow. Cornus officinalis and Dioscorea opposita act as secondary herbs, with the former nourishing liver and kidney and the latter benefiting spleen yin. Oldenlandia diffusa and Scutellaria barbata detoxify, remove blood stasis, relieve pain, and inhibit cancer, while Pheretima aspergillum resolves blood stasis, unblocks meridians, and alleviates pain. Alisma plantago-aquatica drains dampness and purges turbidity, Moutan cortex clears fire and promotes blood circulation to remove blood stasis, and Poria cocos drains dampness from the spleen, all serving as adjuvant herbs. Drynaria fortunei, acting as a guiding herb, tonifies kidney, strengthens bones, and directs the other herbs to the affected area. Together, these herbs work synergistically to tonify the kidney, support healthy qi, resolve blood stasis, disperse nodules, detoxify, and relieve pain.
The Yishen Qutong Granules (Yishen Gu Kang Formula) were granted a patent prescription in 2017 (Patent No.: ZL201310582907.9). In 2020, the research team completed preclinical pharmaceutical studies and obtained approval for the in-house preparation (Beijing Drug Preparation No. Z20200072000). In September 2022, the technology was successfully transferred for a value of 20 million yuan, and the related achievements were awarded the Second Prize of the Beijing Science and Technology Progress Award in the same year. A total of 13 clinical and basic research projects have been conducted around the Yishen Gu Kang Formula, which has also been included in three guidelines, such as the "Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer Pain" by the China Association of Chinese Medicine. The preparation process and quality control standards of Yishen Qutong Granules were established by the Department of Pharmacy at the Cancer Hospital, Chinese Academy of Medical Sciences.
Sample Size Calculation
In this study, the following categorical variables were described using frequencies or percentages, and comparisons between groups were performed using the chi-square test or Fisher's exact test:
For continuous variables in this study, the Shapiro-Wilk test was used to assess normality. If the data followed a normal distribution, they were expressed as mean ± standard deviation, and comparisons between two groups were conducted using the independent samples t-test, while comparisons among multiple groups were performed using one-way ANOVA. If the data did not follow a normal distribution, they were expressed as median (interquartile range), and comparisons between two groups were conducted using the Mann-Whitney U test, while comparisons among multiple groups were performed using the Kruskal-Wallis rank-sum test. The continuous variables included:
All statistical analyses were performed using R software (version 4.0.3). Two-sided tests were applied, and a P-value \<0.05 was considered statistically significant, with a significance level of α=0.05.
Quality Control and Assurance
Quality Assurance Plan: We will conduct regular data audits that encompass both automated data validation and manual review processes. The automated validation will utilize specialized software designed to assess data consistency and completeness, ensuring that all entered data adheres to predefined formats and ranges. Furthermore, annual on-site audits will be scheduled by an independent third-party entity to verify the compliance of data collection and processing procedures. Any discrepancies or errors identified will be documented, and corrective actions will be implemented promptly.
Data Checks: All data inputs will undergo a two-tier verification process. Initially, an automated system will perform a preliminary check based on predefined criteria such as data range, format, and logical relationships to identify potential errors or inconsistencies. Subsequently, research team members will conduct a manual review focusing on data flagged by the automated system and randomly selected additional data entries to ensure the accuracy and reliability of the data.
Source Data Verification: To ensure the accuracy of source data, we will implement a rigorous source data verification procedure. This involves comparing the data in the registry with the original data sources, such as medical records and laboratory reports. We will employ an electronic data capture system to minimize data entry errors and conduct regular checks for data consistency. Moreover, a 100% source data verification will be performed for key variables to guarantee the representativeness and accuracy of the data.
Data Dictionary: Patient ages will be extracted from electronic health records and encoded using WHO standards. All laboratory results will be retrieved from the central laboratory database and encoded according to MedDRA standards. The data dictionary will provide clear guidelines for each variable, ensuring data consistency and comparability.
Standard Operating Procedures (SOPs): We will establish Standard Operating Procedures (SOPs) for all critical operations within the study, including patient recruitment, data collection, data management, data analysis, and adverse event reporting. Each SOP will detail the steps to be taken, the responsible parties, and the timelines, ensuring consistency and reproducibility in all operations. For instance, the patient recruitment SOP will outline the recruitment process, screening criteria, and the informed consent procedure. The data collection SOP will specify the format and timing of data entry, as well as measures for data quality control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(6) Patients who agreeed to participate in this study and sign the form.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On the basis of neoadjuvant concurrent chemoradiotherapy (primarily based on a combination of Paclitaxel/Albumin-bound Paclitaxel, Cisplatin, and Radiotherapy), 10g/bag of Yishen Qutong Granules, 1 sachet per time, Tid, the administration cycle is the same as that of neoadjuvant concurrent chemoradiotherapy
Drug: Yishen Qutong Granules
On the basis of neoadjuvant concurrent chemoradiotherapy (primarily based on a combination of Paclitaxel/Albumin-bound Paclitaxel, Cisplatin, and Radiotherapy), 10g/bag of Yishen Qutong Granules (Yishen Qutong Simulant Granules, 1/10 Yishen Qutong Granules), 1 sachet per time, Tid, the administration cycle is the same as that of neoadjuvant concurrent chemoradiotherapy
Drug: Yishen Qutong Simulant Granules
Neoadjuvant chemotherapy combined with immune drug therapy (primarily based on a combination of Karelizumab, a Platinum-based drug, and either Albumin-bound Paclitaxel or Paclitaxel) based on the use of Yishen Qutong Granules, 10g/dose, Tid treatment, synchronized with immunotherapy and chemotherapy
Drug: Yishen Qutong Granules
Neoadjuvant chemotherapy combined with immune drug therapy (primarily based on a combination of Karelizumab, a Platinum-based drug, and either Albumin-bound Paclitaxel or Paclitaxel) based on the use of Yishen Qutong Simulant granules (1/10 Yishen Qutong Granules), 10g/dose, Tid treatment, used in tandem with immunotherapy, chemotherapy
Drug: Yishen Qutong Simulant Granules
The patent prescription of Professor Feng Li, the head of the Department of Traditional Chinese Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences.
Also known as: YSQTG
Yishen Qutong Simulant Granules is a preparation with one-tenth the dosage of Yishen Qutong Granules.
Also known as: YSQTSG
clinical benefit rate (CBR)
clinical benefit rate, CBR=(CR+PR+SD)
Time frame: Assessed after completion of neoadjuvant therapy (2-4 cycles) and post-surgery, typically within 2-5 months after enrollment.
Symptom Score
Assess the symptom scores of esophageal squamous cell carcinoma using a questionnaire. Esophageal Cancer Obstruction and Dysphagia Symptom Score: 0: No obstruction, does not affect eating at all 1. Very mild sensation of obstruction, does not affect eating 2. Mild obstruction, does not affect eating 3. Mild obstruction but occasionally increased sensation of obstruction, very mildly affects eating, does not affect intake of liquids 4. Mild obstruction, mildly affects eating 5. Mild obstruction but occasionally increased sensation of obstruction, affects eating, including liquids 6. Moderate obstruction, affects eating, including liquids 7. Moderate obstruction and occasionally increased sensation of obstruction, can only swallow liquids 8. Severe obstruction, can only consume very thin liquids 9. Severe obstruction, can only drink water 10. Complete obstruction
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
mPR resection rate
The mPR resection rate is evaluated through postoperative pathology.
Time frame: At the end of the surgery
R0 resection rate
R0 resection rate is evaluated through postoperative pathology.
Time frame: At the end of the surgery
QLQ-C30 scale point
Outcome Measure: Quality of Life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Description: The EORTC QLQ-C30 is a 30-item questionnaire evaluating cancer patients' quality of life across multiple dimensions, including physical, emotional, cognitive, and social functioning, as well as symptom burden (e.g., fatigue, pain, nausea). Scores range from 0 to 100, with higher scores in functional scales and global health status indicating better quality of life, and higher scores in symptom scales indicating worse symptoms. Time Frame: Assessed at baseline, after each treatment cycle (each cycle is 28 days), and at the end of treatment.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
The NRS degree of pain caused by radiation esophagitis
The Numeric Rating Scale (NRS) for pain is a simple and straightforward tool for assessing pain levels. It consists of 11 numbers ranging from 0 to 10, allowing patients to select the number that best represents the intensity of their pain, with 0 indicating no pain and 10 indicating the most severe pain. Pain often comes with an impact on sleep quality. On this NRS scale, 0-3 represents no effect on sleep, 4-6 indicates a mild effect on sleep, and 7-10 signifies an inability to sleep or being awakened by pain. Patients choose a number between 0 and 10 to represent their level of pain intensity. The higher the number, the more severe the pain.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
Evaluation of Syndrome and Symptom Points of Traditional Chinese Medicine
Outcome Measure: Traditional Chinese Medicine (TCM) Syndrome Score. Description: The TCM Syndrome Score evaluates the severity of symptoms related to nodule accumulation, localized pain, tongue appearance, lumbar debility, and fatigue. Each symptom is scored from 0 to 6, with higher scores indicating more severe symptoms. The total score is the sum of individual symptom scores, reflecting the overall severity of TCM syndromes. Time Frame: Assessed at baseline, after each treatment cycle (each cycle is 28 days), and at the end of treatment.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
Progression free survival (PFS)
Progression-Free Survival (PFS) is a commonly used endpoint in oncology clinical research, used to assess the time from the start of treatment to disease progression or death.
Time frame: After the completion of neoadjuvant concurrent therapy, patients will be followed up every 3 months for a total of 8 times (over 2 years), and their progression-free survival (PFS) will be recorded.
pathological complete response rate (pCR)
Pathological complete response (pCR) refers to the absence of viable tumor cells in the resected tumor tissue and regional lymph nodes.
Time frame: Assessed by surgical pathology within 10 days after surgery.
KPS score
The Karnofsky Performance Status (KPS) score is a tool used to assess a patient's functional status and quality of life, and it is widely applied in the fields of oncology and palliative care. 100: Fully active, able to carry on all pre-disease activities without restriction. 90: Capable of normal activity with minor signs or symptoms of disease. 80: Normal activity with effort; some signs or symptoms of disease. 70: Cares for self but unable to carry on normal activity or active work. 60: Requires occasional assistance but is able to care for most of their personal needs. 50: Requires considerable assistance and frequent medical care. 40: Disabled; requires special care and assistance. 30: Severely disabled; hospitalization is indicated although death not imminent. 20: Very sick; hospitalization necessary; active treatment may be indicated. 10: Moribund; fatal processes progressing rapidly. 0: Dead.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
Changes of the tongue
Detect changes in the patient's tongue using a tongue detector.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
Changes of the pulse
Detect changes in the patient's pulse using a pulse detector.
Time frame: Assessed at the end of each treatment cycle (each cycle is 28 days), up to 5 cycles.
Plan to share: No — The project involves some patents that will not be disclosed at this time.
Started Aug 2024 (actual). Primary completion is estimated for Oct 2025, 14 months after the start.
Of 37 interventional studies with no phase under Esophageal Squamous Cell Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →